Inhibrx nagsumite ng BLA para sa ozekibart sa conventional chondrosarcoma

Inhibrx nagsumite ng BLA sa FDA para sa ozekibart sa conventional chondrosarcoma noong Abril 2026. Plano rin ng kumpanya na makipagkita sa FDA sa H2 2026 upang talakayin ang first-line registrational trial sa CRC at potensyal na accelerated pathways para sa fourth-line CRC at refractory Ewing sarcoma.

Mahahalagang fact

Na-file: Abr 21, 2026, 08:04 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Neutral
Kumpanya: INBXInhibrx
Asset: ozekibart
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

inhibrx-20260421 FALSE 0002007919 0002007919 2026-04-21 2026-04-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-42031 99-0613523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11025 N. Torrey Pines Road , Suite 140 La Jolla , CA 92037 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: ( 858 ) 795-4220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy th

SEC 8-K